PAEP and neuroblastoma: Given the activity of ch14.18 against cells expressing GD2, we wanted to determine if ch14.18 scFv might serve as a tool to create an oncolytic HSV-1 for treating neuroblastoma, including investigating if the virus could be retargeted to infect neuroblastoma cells in the absence of a gD interaction with HSV-1 receptors, the functional interaction that triggers wild-type HSV fusion.